Verano Holdings Corp. (VRNO) Posts Fourth Quarter Loss, Surpasses Revenue Projections

Verano Holdings Corp. (VRNO) Reports Quarterly Results

Verano Holdings Corp. (VRNO) posted a quarterly loss of $0.10 per share, which was wider than the consensus estimate of a $0.06 loss. In comparison, the company reported a $0.04 per share loss in the same period last year. These results have been adjusted to exclude one-time items.

This quarter, the company missed earnings expectations by 66.67%. In the previous quarter, analysts anticipated a $0.05 per share loss, but the actual loss was $0.12, resulting in a negative surprise of 140%.

Over the past year, Verano Holdings has only exceeded consensus earnings per share estimates once.

For the quarter ending December 2025, Verano Holdings, a member of the Zacks Medical - Products sector, generated $206.61 million in revenue, slightly ahead of the consensus estimate by 0.36%. This figure is down from $218.21 million in the same quarter last year. The company has only outperformed revenue expectations once in the last four quarters.

The future direction of the stock will largely depend on management’s insights during the earnings call, as well as future earnings projections.

Since the start of the year, Verano Holdings shares have declined by approximately 11.1%, compared to a 1% drop in the S&P 500 index.

What Lies Ahead for Verano Holdings Corp.?

Despite lagging behind the broader market this year, investors are now considering what the future holds for Verano Holdings Corp.

While there is no definitive answer, a key factor to watch is the company’s earnings outlook. This includes not only current consensus forecasts for upcoming quarters, but also any recent changes to those estimates.

Research indicates that short-term stock price movements are closely linked to changes in earnings estimates. Investors can monitor these revisions themselves or use established tools like the Zacks Rank, which has a strong track record of leveraging earnings estimate trends.

Before this earnings announcement, estimate revisions for Verano Holdings Corp. were mixed. Following the latest results, the company currently holds a Zacks Rank #3 (Hold), suggesting the stock is likely to perform in line with the market in the near term.

It will be important to watch how analyst estimates for the next quarters and the current fiscal year evolve. At present, the consensus projects an EPS of -$0.07 on $203.57 million in revenue for the next quarter, and an EPS of -$0.22 on $840.58 million in revenue for the full year.

Investors should also consider the broader industry outlook, as it can significantly affect the stock’s performance. The Medical - Products industry currently ranks in the bottom 40% among over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperforms the lower half by more than two to one.

Industry Comparison: Neogen (NEOG)

Another company in the same sector, Neogen (NEOG), has not yet released its results for the quarter ending February 2026.

Neogen, which produces medical testing kits, is anticipated to report quarterly earnings of $0.04 per share, representing a 60% decrease from the previous year. Over the past month, the consensus EPS estimate for Neogen has been revised downward by 8.3%.

Neogen’s revenue is expected to reach $204.46 million, a 7.5% decline compared to the same quarter last year.

Is Verano Holdings Corp. (VRNO) a Good Investment?

If you’re considering investing in Verano Holdings Corp. (VRNO), you may want to explore the top stock picks for the next month. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided investors with independent analysis and tools. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of +24.08%, more than doubling the S&P 500’s performance from January 1, 1988, through May 6, 2024.

Looking for the latest stock recommendations from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days for free.